Ask Us
Please correct the highlighted fields below.

Alerts for Topiramate

Title Date Published Source
La AEMPS Alerta Sobre el Riesgo de Defectos Orales al Nacer en Niños de Madres Que Toman Topiramato 2011-12-15
TGA Warns About Reports of Adverse Effect When Topiramate Used to Assist with Weight Loss 2011-10-05
Teva Pharmaceuticals USA, Inc. Recalls Select Lots of Topiramate Tablets, 25 mg 2011-04-25
Ortho-McNeil Voluntarily Recalls Two Lots of Topamax 100 mg 2011-04-14
Emra-med Arzneimittel GmbH ruft eine Charge Topamax 25 mg Filmtabletten zurueck 2011-03-08
FDA Warns About Risk of Oral Birth Defects in Children Born to Mothers Taking Topiramate 2011-03-05
Recall Topamax: Safety Warnings Not Included in Patient Information Leaflet 2010-04-01
FDA Approves Updated Labeling For Antiepileptic Medications 2009-05-06
New FDA Warning on Seizure Medications 2008-12-17
Potential increased risk of birth defects 2008-08-11
Increased risk of suicidal thoughts and behaviour 2008-01-31

See alerts for all drugs

Tell a friend

DISCLAIMER: MediGuard is not intended to be a substitute for professional medical advice. MediGuard cannot and does not take into consideration every possible interaction or account for individual responses to medicine. Different individuals may respond to medication in different ways. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Always seek the advice of a qualified health provider with any questions you may have before making any changes to your treatment. The use of the MediGuard site and its content is at your own risk. The MediGuard site and the information contained in it is intended for users in the United States and information in other countries may be different.

Popular Terms: Lisinopril Side Effects, Plavix Side Effects, Copaxone Information, Metformin, Methotrexate Interactions

HACKER SAFE certified sites prevent over 99.9% of hacker crime.